REGENXBIO Inc. has announced a strategic royalty monetization agreement with Healthcare Royalty (HCRx) valued at up to $250 million. The agreement involves a non-dilutive, limited recourse royalty bond, allowing REGENXBIO to monetize select anticipated royalties and milestones. The company received an immediate $150 million at closing, extending its cash runway into early 2027. This financing will support REGENXBIO's commercial preparations and late-stage activities, while also retaining potential future non-dilutive funding opportunities. The deal underlines REGENXBIO's position as a leader in rare and retinal gene therapies, aiming to unlock significant value for shareholders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。